Johnson & Johnson (NYSE:JNJ) Shares Sold by Richwood Investment Advisors LLC

Richwood Investment Advisors LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 6.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,621 shares of the company’s stock after selling 247 shares during the quarter. Richwood Investment Advisors LLC’s holdings in Johnson & Johnson were worth $567,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in JNJ. 4J Wealth Management LLC grew its stake in Johnson & Johnson by 2.2% during the fourth quarter. 4J Wealth Management LLC now owns 2,835 shares of the company’s stock worth $444,000 after buying an additional 62 shares during the last quarter. My Personal CFO LLC grew its stake in shares of Johnson & Johnson by 1.4% during the fourth quarter. My Personal CFO LLC now owns 4,550 shares of the company’s stock valued at $713,000 after purchasing an additional 62 shares during the last quarter. Eagle Strategies LLC grew its stake in shares of Johnson & Johnson by 1.8% during the fourth quarter. Eagle Strategies LLC now owns 3,589 shares of the company’s stock valued at $563,000 after purchasing an additional 63 shares during the last quarter. Clearview Wealth Advisors LLC grew its stake in shares of Johnson & Johnson by 1.5% during the fourth quarter. Clearview Wealth Advisors LLC now owns 4,373 shares of the company’s stock valued at $685,000 after purchasing an additional 64 shares during the last quarter. Finally, Brookmont Capital Management grew its stake in shares of Johnson & Johnson by 0.4% during the fourth quarter. Brookmont Capital Management now owns 14,852 shares of the company’s stock valued at $2,328,000 after purchasing an additional 64 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.9 %

JNJ traded down $1.39 during mid-day trading on Friday, hitting $148.31. The stock had a trading volume of 1,400,261 shares, compared to its average volume of 7,299,794. The stock’s fifty day simple moving average is $151.53 and its 200-day simple moving average is $155.07. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. The firm has a market capitalization of $356.93 billion, a price-to-earnings ratio of 9.25, a price-to-earnings-growth ratio of 2.55 and a beta of 0.55. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period last year, the business posted $2.68 earnings per share. As a group, research analysts forecast that Johnson & Johnson will post 10.64 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.34%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date is Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Monday, May 6th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Bank of America decreased their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $175.00 price objective on shares of Johnson & Johnson in a research note on Wednesday. Finally, HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price objective for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $175.86.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.